Wild parsnip

A reader wrote last week how she had been trying for a couple of years to identify a tall yellow-flowered roadside weed until someone told her it was wild parsnip. Unable to find much information about it, she turned to this column.

Wild parsnip, Pastinaca sativa, is among the rapidly increasing weeds in many areas. As wild parsnip has spread, so has the realization that human exposure often leads to serious burns and blisters on the arms and legs. Being able to readily identify wild parsnip and early detection of infested areas will minimize inadvertent and excessive exposure to this plant and the often painful results that follow.

The species is native to Eurasia, and may have been introduced as a vegetable as plants have long, thick, white to yellowish taproots that are edible. True parsnip plants have larger roots than wild parsnip. The entire plant has a parsnip odor. Cattle will not eat wild parsnip but deer may feed on it, and birds and small mammals eat the seeds.

The plants are most abundant in sites dominated by perennial grasses that are mowed once or twice a year.

Why the explosion of wild parsnip? Only Mother Nature knows for sure. Birds and mammals eat the seeds and they may be spreading the problem from site to site. There is no doubt that the delay in mowing roadsides until mid summer as an official roadside management policy of the state and towns opens the door for this plant to complete its life cycle, and produce ripe seeds well before any mowing is done. Wild parsnip is tolerant of a wide range of conditions, including dry and wet areas. It is shade tolerant, but prefers sunny conditions. Depending on the habitat and growing conditions, individual flowering plants range to over four feet in height.

Also, when roadsides and pastures are mowed in July and August, parsnip seeds probably move as hitchhikers on the mowers. Mowing also creates a much more favorable environment for parsnip seeds to germinate than if the sites were left undisturbed. Relatively mild winters may enhance survival of wild parsnip plants that germinate and become established in the fall.

Wild parsnip has a long germination period, but the optimum time for germination is in the early spring, and that is when most germination occurs. Most fall germinated seedlings die during winter. Wild parsnip seedlings are among the first plants to greenup early in the spring.

Rosettes grow close to the ground and bear leaves averaging six inches in height. Flowering plants produce a single, thick stem that contains hundreds of yellow umbellate flowers. The lateral flowers often overtop the terminal flowers.

But, the most important thing for humans to remember is to avoid contact with the plant. Humans develop a severe skin irritation from contact with its leaves. Plants have chemicals called psoralens that cause an interaction between plant and light that induce skin inflammation.

Experts are warning people to stay away from wild parsnip after a Vermont woman was severely burned after being exposed to the sap.

The plant grows along rural roads and in meadows throughout the state. Wild parsnip is not native to Maine and has a deep vertical ridge on its stalk. The flowers come in clusters of tiny yellow flowers similar to Queen Annes Lace.

A woman in Vermont fell into a wild parsnip plant and suffered horrific burns after her legs were exposed to the sap and she spent time in the sun.

It is soluble, said Maine State Horticulturist Gary Fish. It goes into the skin and thats when you are going to have damage to the skin which turns into blisters when you have sun exposure.

People walking through vegetation should wear long sleeves and pants and stay away from plants that look like wild parsnips.

Wild parsnip has sap that has psoralens in it naturally occurring organic compounds that can kill skin cells that protect people from ultraviolet radiation. When the sap touches the body, it can cause blisters and symptoms resembling symptoms from a burn.

Once the sap is absorbed by the skin, they are energized by UV light on both sunny and cloudy days. They then bind to DNA and cell membranes, destroying cells and skin. Parsnip burns usually occur in streaks and elongated spots, reflecting where a damaged leaf or stem moved across the skin before exposure to sunlight.

Wild parsnip burns differ from the rash caused by poison ivy in several aspects. First, everyone is sensitive to wild parsnip and you do not need to be sensitized by a prior exposure to develop burns or blisters. You can brush against wild parsnip plants and not be affected. Parsnip is dangerous only when the plant sap from broken leaves or stems gets on your skin. Lastly, the parsnip burn is usually less irritating than poison ivys itch.

After about 3 days, the symptoms start to get better. Eventually, like after a bad sunburn, the burned skin cells die and flake off. As symptoms improve, the rash may appear lighter or darker. Discoloration and sensitivity to sunlight in the affected areas can remain for up to two years.

Wild parsnip grows abundantly on our roadsides. Some people mistake it as ragweed, and rightfully so. There is, however, many dissimilarities once you see them side by side.

If you develop a rash or blisters, go to the hospital or a clinic for treatment.

There are other plants in the family that can be harmful as well: Cow Parsnip, a native plant, with white flowers; Giant Hogweed, an invasive species, with white flowers similar to cow parsnip.

When it comes to wild parsnip, unless you are absolutely sure it is something else, dont touch it.

In 1975, the Red Sox played the Cincinnati Reds in what is called the Greatest World Series ever. Who hit an eighth inning three-run homer in game 6 to tie the score, and set up Carlton Fisks 12th inning iconic home run?

Answer can be found here.

The Town Line is a 501(c)(3) nonprofit private foundation, and all donations are tax deductible under the Internal Revenue Service code.

To help, please visit our online donation page or mail a check payable to The Town Line, POBox 89, South China, ME 04358. Your contribution is appreciated!

Read more from the original source:
SCORES & OUTDOORS - Be cautious of the wild parsnip - Town Line

Skin Stem Cells Comments Off on SCORES & OUTDOORS – Be cautious of the wild parsnip – Town Line | August 19th, 2020

KENILWORTH, N.J.--(BUSINESS WIRE)--Aug 19, 2020--

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, in combination with chemotherapy (cisplatin plus 5-fluorouracil [5-FU]), met its primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of patients with locally advanced or metastatic esophageal cancer. Based on an interim analysis conducted by an independent Data Monitoring Committee, KEYTRUDA in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS and PFS compared with chemotherapy (cisplatin plus 5-FU), the current standard of care, in the intention-to-treat (ITT) population. The study also met the key secondary endpoint of objective response rate (ORR), with significant improvements for KEYTRUDA in combination with chemotherapy compared with chemotherapy alone. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies. Results will be shared with global regulatory authorities and have been submitted for presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Esophageal cancer is a devastating malignancy with a high mortality rate and few treatment options in the first-line setting beyond chemotherapy, said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. In this pivotal study, KEYTRUDA plus chemotherapy resulted in superior overall survival compared with the current standard of care in the full study population and across all patient groups evaluated. These results build upon our research reinforcing the survival benefits of KEYTRUDA, and we look forward to engaging regulatory authorities as quickly as possible.

KEYTRUDA is currently approved in the U.S. and China as monotherapy for the second-line treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] 10). Merck is continuing to study KEYTRUDA across multiple settings and stages of gastrointestinal cancer including gastric, hepatobiliary, esophageal, pancreatic, colorectal and anal cancers through its broad clinical program.

About KEYNOTE-590

KEYNOTE-590 is a randomized, double-blind, Phase 3 trial (ClinicalTrials.gov, NCT03189719 ) evaluating KEYTRUDA in combination with chemotherapy compared with placebo plus chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal carcinoma (adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type 1 adenocarcinoma of the esophagogastric junction). The primary endpoints are OS and PFS. The secondary endpoints include ORR, duration of response and safety. The study enrolled 749 patients who were randomized to receive:

About Esophageal Cancer

Esophageal cancer, a type of cancer that is particularly difficult to treat, begins in the inner layer (mucosa) of the esophagus and grows outward. The two main types of esophageal cancer are squamous cell carcinoma and adenocarcinoma. Esophageal cancer is the seventh most commonly diagnosed cancer and the sixth leading cause of death from cancer worldwide. Globally, it is estimated there were more than 572,000 new cases of esophageal cancer diagnosed and nearly 509,000 deaths resulting from the disease in 2018. In the U.S. alone, it is estimated there will be nearly 18,500 new cases of esophageal cancer diagnosed and more than 16,000 deaths resulting from the disease in 2020.

About KEYTRUDA (pembrolizumab) Injection, 100 mg

KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the bodys immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.

Merck has the industrys largest immuno-oncology clinical research program. There are currently more than 1,200 trials studying KEYTRUDA across a wide variety of cancers and treatment settings. The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient's likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Selected KEYTRUDA (pembrolizumab) Indications

Melanoma

KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.

KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.

Non-Small Cell Lung Cancer

KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.

KEYTRUDA, in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, is indicated for the first-line treatment of patients with metastatic squamous NSCLC.

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with NSCLC expressing PD-L1 [tumor proportion score (TPS) 1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Small Cell Lung Cancer

KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other prior line of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Head and Neck Squamous Cell Cancer

KEYTRUDA, in combination with platinum and fluorouracil (FU), is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).

KEYTRUDA, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [combined positive score (CPS) 1] as determined by an FDA-approved test.

KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy.

Classical Hodgkin Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Primary Mediastinal Large B-Cell Lymphoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.

Urothelial Carcinoma

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 [combined positive score (CPS) 10], as determined by an FDA-approved test, or in patients who are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

KEYTRUDA is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

KEYTRUDA is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

Microsatellite Instability-High or Mismatch Repair Deficient Cancer

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.

Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer

KEYTRUDA is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).

Gastric Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Esophageal Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS 10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Cervical Cancer

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS 1) as determined by an FDA-approved test. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Hepatocellular Carcinoma

KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Merkel Cell Carcinoma

KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.

Renal Cell Carcinoma

KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

Tumor Mutational Burden-High

KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established.

Cutaneous Squamous Cell Carcinoma

KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Selected Important Safety Information for KEYTRUDA

Immune-Mediated Pneumonitis

KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases. Pneumonitis occurred in 3.4% (94/2799) of patients with various cancers receiving KEYTRUDA, including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%). Pneumonitis occurred in 8.2% (65/790) of NSCLC patients receiving KEYTRUDA as a single agent, including Grades 3-4 in 3.2% of patients, and occurred more frequently in patients with a history of prior thoracic radiation (17%) compared to those without (7.7%). Pneumonitis occurred in 6% (18/300) of HNSCC patients receiving KEYTRUDA as a single agent, including Grades 3-5 in 1.6% of patients, and occurred in 5.4% (15/276) of patients receiving KEYTRUDA in combination with platinum and FU as first-line therapy for advanced disease, including Grades 3-5 in 1.5% of patients.

Monitor patients for signs and symptoms of pneumonitis. Evaluate suspected pneumonitis with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2 pneumonitis.

Immune-Mediated Colitis

KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 1.7% (48/2799) of patients receiving KEYTRUDA, including Grade 2 (0.4%), 3 (1.1%), and 4 (<0.1%). Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for Grade 4 colitis.

Immune-Mediated Hepatitis (KEYTRUDA) and Hepatotoxicity (KEYTRUDA in Combination With Axitinib)

Immune-Mediated Hepatitis

KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 0.7% (19/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.4%), and 4 (<0.1%). Monitor patients for changes in liver function. Administer corticosteroids for Grade 2 or greater hepatitis and, based on severity of liver enzyme elevations, withhold or discontinue KEYTRUDA.

Hepatotoxicity in Combination With Axitinib

KEYTRUDA in combination with axitinib can cause hepatic toxicity with higher than expected frequencies of Grades 3 and 4 ALT and AST elevations compared to KEYTRUDA alone. With the combination of KEYTRUDA and axitinib, Grades 3 and 4 increased ALT (20%) and increased AST (13%) were seen. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider more frequent monitoring of liver enzymes as compared to when the drugs are administered as single agents. For elevated liver enzymes, interrupt KEYTRUDA and axitinib, and consider administering corticosteroids as needed.

Immune-Mediated Endocrinopathies

KEYTRUDA can cause adrenal insufficiency (primary and secondary), hypophysitis, thyroid disorders, and type 1 diabetes mellitus. Adrenal insufficiency occurred in 0.8% (22/2799) of patients, including Grade 2 (0.3%), 3 (0.3%), and 4 (<0.1%). Hypophysitis occurred in 0.6% (17/2799) of patients, including Grade 2 (0.2%), 3 (0.3%), and 4 (<0.1%). Hypothyroidism occurred in 8.5% (237/2799) of patients, including Grade 2 (6.2%) and 3 (0.1%). The incidence of new or worsening hypothyroidism was higher in 1185 patients with HNSCC (16%) receiving KEYTRUDA, as a single agent or in combination with platinum and FU, including Grade 3 (0.3%) hypothyroidism. Hyperthyroidism occurred in 3.4% (96/2799) of patients, including Grade 2 (0.8%) and 3 (0.1%), and thyroiditis occurred in 0.6% (16/2799) of patients, including Grade 2 (0.3%). Type 1 diabetes mellitus, including diabetic ketoacidosis, occurred in 0.2% (6/2799) of patients.

Monitor patients for signs and symptoms of adrenal insufficiency, hypophysitis (including hypopituitarism), thyroid function (prior to and periodically during treatment), and hyperglycemia. For adrenal insufficiency or hypophysitis, administer corticosteroids and hormone replacement as clinically indicated. Withhold KEYTRUDA for Grade 2 adrenal insufficiency or hypophysitis and withhold or discontinue KEYTRUDA for Grade 3 or Grade 4 adrenal insufficiency or hypophysitis. Administer hormone replacement for hypothyroidism and manage hyperthyroidism with thionamides and beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism. Administer insulin for type 1 diabetes, and withhold KEYTRUDA and administer antihyperglycemics in patients with severe hyperglycemia.

Immune-Mediated Nephritis and Renal Dysfunction

KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 0.3% (9/2799) of patients receiving KEYTRUDA, including Grade 2 (0.1%), 3 (0.1%), and 4 (<0.1%) nephritis. Nephritis occurred in 1.7% (7/405) of patients receiving KEYTRUDA in combination with pemetrexed and platinum chemotherapy. Monitor patients for changes in renal function. Administer corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for Grade 2; permanently discontinue for Grade 3 or 4 nephritis.

Immune-Mediated Skin Reactions

Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Monitor patients for suspected severe skin reactions and based on the severity of the adverse reaction, withhold or permanently discontinue KEYTRUDA and administer corticosteroids. For signs or symptoms of SJS or TEN, withhold KEYTRUDA and refer the patient for specialized care for assessment and treatment. If SJS or TEN is confirmed, permanently discontinue KEYTRUDA.

Other Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue in patients receiving KEYTRUDA and may also occur after discontinuation of treatment. For suspected immune-mediated adverse reactions, ensure adequate evaluation to confirm etiology or exclude other causes. Based on the severity of the adverse reaction, withhold KEYTRUDA and administer corticosteroids. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less following corticosteroid taper. Permanently discontinue KEYTRUDA for any Grade 3 immune-mediated adverse reaction that recurs and for any life-threatening immune-mediated adverse reaction.

The following clinically significant immune-mediated adverse reactions occurred in less than 1% (unless otherwise indicated) of 2799 patients: arthritis (1.5%), uveitis, myositis, Guillain-Barr syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, sarcoidosis, and encephalitis. In addition, myelitis and myocarditis were reported in other clinical trials, including classical Hodgkin lymphoma, and postmarketing use.

Treatment with KEYTRUDA may increase the risk of rejection in solid organ transplant recipients. Consider the benefit of treatment vs the risk of possible organ rejection in these patients.

Infusion-Related Reactions

KEYTRUDA can cause severe or life-threatening infusion-related reactions, including hypersensitivity and anaphylaxis, which have been reported in 0.2% (6/2799) of patients. Monitor patients for signs and symptoms of infusion-related reactions. For Grade 3 or 4 reactions, stop infusion and permanently discontinue KEYTRUDA.

Complications of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Immune-mediated complications, including fatal events, occurred in patients who underwent allogeneic HSCT after treatment with KEYTRUDA. Of 23 patients with cHL who proceeded to allogeneic HSCT after KEYTRUDA, 6 (26%) developed graft-versus-host disease (GVHD) (1 fatal case) and 2 (9%) developed severe hepatic veno-occlusive disease (VOD) after reduced-intensity conditioning (1 fatal case). Cases of fatal hyperacute GVHD after allogeneic HSCT have also been reported in patients with lymphoma who received a PD-1 receptorblocking antibody before transplantation. Follow patients closely for early evidence of transplant-related complications such as hyperacute graft-versus-host disease (GVHD), Grade 3 to 4 acute GVHD, steroid-requiring febrile syndrome, hepatic veno-occlusive disease (VOD), and other immune-mediated adverse reactions.

In patients with a history of allogeneic HSCT, acute GVHD (including fatal GVHD) has been reported after treatment with KEYTRUDA. Patients who experienced GVHD after their transplant procedure may be at increased risk for GVHD after KEYTRUDA. Consider the benefit of KEYTRUDA vs the risk of GVHD in these patients.

Increased Mortality in Patients With Multiple Myeloma

In trials in patients with multiple myeloma, the addition of KEYTRUDA to a thalidomide analogue plus dexamethasone resulted in increased mortality. Treatment of these patients with a PD-1 or PD-L1 blocking antibody in this combination is not recommended outside of controlled trials.

Embryofetal Toxicity

Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. Advise women of this potential risk. In females of reproductive potential, verify pregnancy status prior to initiating KEYTRUDA and advise them to use effective contraception during treatment and for 4 months after the last dose.

Adverse Reactions

In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9% of 555 patients with advanced melanoma; adverse reactions leading to permanent discontinuation in more than one patient were colitis (1.4%), autoimmune hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and cardiac failure (0.4%). The most common adverse reactions (20%) with KEYTRUDA were fatigue (28%), diarrhea (26%), rash (24%), and nausea (21%).

In KEYNOTE-002, KEYTRUDA was permanently discontinued due to adverse reactions in 12% of 357 patients with advanced melanoma; the most common (1%) were general physical health deterioration (1%), asthenia (1%), dyspnea (1%), pneumonitis (1%), and generalized edema (1%). The most common adverse reactions were fatigue (43%), pruritus (28%), rash (24%), constipation (22%), nausea (22%), diarrhea (20%), and decreased appetite (20%).

In KEYNOTE-054, KEYTRUDA was permanently discontinued due to adverse reactions in 14% of 509 patients; the most common (1%) were pneumonitis (1.4%), colitis (1.2%), and diarrhea (1%). Serious adverse reactions occurred in 25% of patients receiving KEYTRUDA. The most common adverse reaction (20%) with KEYTRUDA was diarrhea (28%).

In KEYNOTE-189, when KEYTRUDA was administered with pemetrexed and platinum chemotherapy in metastatic nonsquamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 20% of 405 patients. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonitis (3%) and acute kidney injury (2%). The most common adverse reactions (20%) with KEYTRUDA were nausea (56%), fatigue (56%), constipation (35%), diarrhea (31%), decreased appetite (28%), rash (25%), vomiting (24%), cough (21%), dyspnea (21%), and pyrexia (20%).

In KEYNOTE-407, when KEYTRUDA was administered with carboplatin and either paclitaxel or paclitaxel protein-bound in metastatic squamous NSCLC, KEYTRUDA was discontinued due to adverse reactions in 15% of 101 patients. The most frequent serious adverse reactions reported in at least 2% of patients were febrile neutropenia, pneumonia, and urinary tract infection. Adverse reactions observed in KEYNOTE-407 were similar to those observed in KEYNOTE-189 with the exception that increased incidences of alopecia (47% vs 36%) and peripheral neuropathy (31% vs 25%) were observed in the KEYTRUDA and chemotherapy arm compared to the placebo and chemotherapy arm in KEYNOTE-407.

In KEYNOTE-042, KEYTRUDA was discontinued due to adverse reactions in 19% of 636 patients with advanced NSCLC; the most common were pneumonitis (3%), death due to unknown cause (1.6%), and pneumonia (1.4%). The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia (7%), pneumonitis (3.9%), pulmonary embolism (2.4%), and pleural effusion (2.2%). The most common adverse reaction (20%) was fatigue (25%).

In KEYNOTE-010, KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of 682 patients with metastatic NSCLC; the most common was pneumonitis (1.8%). The most common adverse reactions (20%) were decreased appetite (25%), fatigue (25%), dyspnea (23%), and nausea (20%).

Adverse reactions occurring in patients with SCLC were similar to those occurring in patients with other solid tumors who received KEYTRUDA as a single agent.

In KEYNOTE-048, KEYTRUDA monotherapy was discontinued due to adverse events in 12% of 300 patients with HNSCC; the most common adverse reactions leading to permanent discontinuation were sepsis (1.7%) and pneumonia (1.3%). The most common adverse reactions (20%) were fatigue (33%), constipation (20%), and rash (20%).

In KEYNOTE-048, when KEYTRUDA was administered in combination with platinum (cisplatin or carboplatin) and FU chemotherapy, KEYTRUDA was discontinued due to adverse reactions in 16% of 276 patients with HNSCC. The most common adverse reactions resulting in permanent discontinuation of KEYTRUDA were pneumonia (2.5%), pneumonitis (1.8%), and septic shock (1.4%). The most common adverse reactions (20%) were nausea (51%), fatigue (49%), constipation (37%), vomiting (32%), mucosal inflammation (31%), diarrhea (29%), decreased appetite (29%), stomatitis (26%), and cough (22%).

In KEYNOTE-012, KEYTRUDA was discontinued due to adverse reactions in 17% of 192 patients with HNSCC. Serious adverse reactions occurred in 45% of patients. The most frequent serious adverse reactions reported in at least 2% of patients were pneumonia, dyspnea, confusional state, vomiting, pleural effusion, and respiratory failure. The most common adverse reactions (20%) were fatigue, decreased appetite, and dyspnea. Adverse reactions occurring in patients with HNSCC were generally similar to those occurring in patients with melanoma or NSCLC who received KEYTRUDA as a monotherapy, with the exception of increased incidences of facial edema and new or worsening hypothyroidism.

In KEYNOTE-087, KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients with cHL. Serious adverse reactions occurred in 16% of patients; those 1% included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and herpes zoster. Two patients died from causes other than disease progression; 1 from GVHD after subsequent allogeneic HSCT and 1 from septic shock. The most common adverse reactions (20%) were fatigue (26%), pyrexia (24%), cough (24%), musculoskeletal pain (21%), diarrhea (20%), and rash (20%).

In KEYNOTE-170, KEYTRUDA was discontinued due to adverse reactions in 8% of 53 patients with PMBCL. Serious adverse reactions occurred in 26% of patients and included arrhythmia (4%), cardiac tamponade (2%), myocardial infarction (2%), pericardial effusion (2%), and pericarditis (2%). Six (11%) patients died within 30 days of start of treatment. The most common adverse reactions (20%) were musculoskeletal pain (30%), upper respiratory tract infection and pyrexia (28% each), cough (26%), fatigue (23%), and dyspnea (21%).

Read this article:
Merck's KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With...

Skin Stem Cells Comments Off on Merck’s KEYTRUDA (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With… | August 19th, 2020

New York, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hydrogels Industry" - https://www.reportlinker.com/p05896103/?utm_source=GNW Strong R&D interest is already underway for hydrogel biomaterials. New developments in hydrogel design and hydrogel synthesis are resulting in the development of hydrogels with mechanical properties. Superporous comb-type grafted hydrogels with fast response times; hybrid graft copolymers based self-assembling hydrogels; protein based hydrogels and hybrid hydrogels are the emerging new future of smart hydrogel based biomaterials. Stimuli-sensitive hydrogels, especially polypeptide based responsive hydrogels hold promising potential. Protein hydrogel are more biocompatible than synthetic hydrogel as they do not require the use of oxic chemical crosslinkers. This represents a key growth opportunity in the market given that traditional hydrogels have been largely limited by their poor mechanical properties and slow response times to stimuli. Temperature-sensitive hydrogels especially will find attractive opportunities in biomedicine.

Wound dressings currently remain a popular application area with hydrogel being effective for treating dry necrotic wounds and rapid healing of burn wounds. Hydrogel enables painless debridement of infected tissue and provides a moist wound environment for faster healing. Chitosan-based hydrogels, in this regard, are growing in popularity for their biocompatible, antimicrobial, and hemostatic effects. Acellular Hydrogel is especially valuable in accelerated healing of third-degree burn wounds and is a welcome substitute for complicated and infection prone skin grafts. Encouraging progress is being made in the use of hydrogels for targeted & controlled drug delivery. Hydrogels can prolong drug release kinetics. Their porosity and aqueous features make them perfect biocompatible drug delivery vehicles. Chitosan-based hydrogels can be loaded with active drug compounds like growth factors or stem cells that are important in providing scaffold for cell growth. The growing focus on controlled and targeted drug delivery systems in the field of cardiology, oncology, immunology, and pain management bodes well for future growth in the market. Some of the physical properties of hydrogel that can be manipulated and tuned to suit drug delivery needs include porosity, swelling and elasticity in response to stimuli such as temperature, solvent quality, pH, electric field; resistance to dissolution; free diffusion of solute molecules in water; among others. These properties help in controlled drug release and protect from drug degradation, thereby making them highly effective vehicles for drug delivery systems. Some of the types of hydrogels development for drug delivery include DNA-hydrogels; supramolecular hydrogels; bio-inspired hydrogels; and multi-functional and stimuli-responsive hydrogels. New emerging uses in contact lenses and tissue engineering will also benefit growth in the market in the coming years. The United States and Europe represent large markets worldwide with a combined share of 52.4% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by the governments focus on revolutionizing biomedical engineering in the country. The country today ranks as the top country for biomedical research encouraged by a permissive regulatory climate.

Read the full report: https://www.reportlinker.com/p05896103/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Expanding Applications and Product Innovations Spur Growth in the Global Hydrogel Market Emerging Economies to Post Strong Growth Industry Witnesses Rise in Demand for Synthetic Hydrogels Synthetic Hydrogels by Polymer Type: A Snapshot Global Competitor Market Shares Hydrogel Competitor Market Share Scenario Worldwide (in %): 2019 Hydrogel Competitor Market Share Scenario Worldwide (in %): 2019

2. FOCUS ON SELECT PLAYERS 3M Company (USA) ACELITY L.P, Inc. (USA) Ashland, Inc. (USA) Braun Melsungen AG (Germany) Cardinal Health, Inc. (USA) Coloplast A/S (Denmark) ConvaTec, Inc. (USA) Integra LifeSciences Holdings Corporation (USA) Evonik Industries AG (Germany) Gentell, Inc. (USA) Hollister, Inc. (USA) Mlnlycke Health Care AB (Sweden) Ocular Therapeutix, Inc. (USA) Sekisui Plastics Co. Ltd. (Japan) Smith & Nephew, Plc (UK)

3. MARKET TRENDS & DRIVERS Innovations Expand Addressable Market for Hydrogels Rise in Incidence of Chronic Diseases and High Treatment Costs Drive Demand for Hydrogel Dressings for Wound Healing Global Prevalence of Wounds Global Wound Care Market: Percentage Breakdown of Spending by Wound Type Personal Care Product: An Evolving Niche Market Global Skin Care Market Size in US$ Billion for the Years 2019, 2021, 2023 and 2025 Consumer Adoption of Hydrogel Contact Lenses Augurs Well for Market Growth Global Contact Lens Fits by Category (In %): 2019 Hydrogels Evolve as Emerging Alternative for Food Packaging Agriculture Sector Depicts Strong Growth Potential Global Water Utilization: Percentage Share Breakdown for Agricultural Practices, Industrial Processes, and Domestic Usage Rising Concerns over Polluting Water Resources: An Opportunity for Hydrogels Market Need for Wastewater Treatment Presents Opportunity for Hydrogels: Percentage of Wastewater Treated in Europe, Asia, Latin America, and Africa Growing Emphasis on Sustainability and Positive Impact on Hydrogels Growth in Biomedical Applications of Hydrogels Hydrogels for Cartilage Regeneration Growing Need for Targeted Controlled Drug Delivery (TCDD) Drives Importance of Hydrogels Hydrogel Nanoparticles: The New Hydrogels for Drug Delivery Evaporative Cooling Hydrogel Packaging: Increasing Storage Stability of Pharmaceuticals Growing Focus on Baby Hygiene Products Spells Steady Growth Opportunities for Hydrogels Annual Usage of Baby Disposable Diapers Per Infant by Region: ( Age upto 2.5 years) Global New Births (in Millions) per Annum by Geographic Region World Fertility Rate in % by Region (2013 & 2050F) Increased Demand for Feminine Hygiene Products Global Female Population by Geographic Region: Percentage Breakdown by Region for 2018 Number of Menstruating Women Worldwide by Country: 15-49 Years Female Population (in Millions) for 2013 & 2025P Aging Population and the Associated Complications Drive the Demand for Hydrogel Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Rise in Demand for Novel Hydrogel Dressings for Wound Healing Propels Innovations PRODUCT OVERVIEW Hydrogel Types of Hydrogel Natural Hydrogels Select Natural Hydrogels: Advantages and Disadvantages Synthetic Hydrogels Select Synthetic Hydrogels: Advantages and Disadvantages Hybrid Hydrogels

4. GLOBAL MARKET PERSPECTIVE Table 1: Hydrogels Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 2: Hydrogels Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019

Table 3: Hydrogels Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027

Table 4: Natural (Raw Material) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 5: Natural (Raw Material) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 6: Natural (Raw Material) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027

Table 7: Synthetic (Raw Material) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027

Table 8: Synthetic (Raw Material) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019

Table 9: Synthetic (Raw Material) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027

Table 10: Hybrid (Raw Material) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027

Table 11: Hybrid (Raw Material) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019

Table 12: Hybrid (Raw Material) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 13: Polyacrylate (Composition) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027

Table 14: Polyacrylate (Composition) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 15: Polyacrylate (Composition) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

Table 16: Polyacrylamide (Composition) World Market by Region/Country in US$ Thousand: 2020 to 2027

Table 17: Polyacrylamide (Composition) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019

Table 18: Polyacrylamide (Composition) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 19: Silicon (Composition) World Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020 to 2027

Table 20: Silicon (Composition) Market Worldwide Historic Review by Region/Country in US$ Thousand: 2012 to 2019

Table 21: Silicon (Composition) Market Percentage Share Distribution by Region/Country: 2012 VS 2020 VS 2027

Table 22: Other Compositions (Composition) Market Opportunity Analysis Worldwide in US$ Thousand by Region/Country: 2020 to 2027

Table 23: Other Compositions (Composition) Global Historic Demand in US$ Thousand by Region/Country: 2012 to 2019

Table 24: Other Compositions (Composition) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027

Table 25: Agriculture (Application) Worldwide Sales in US$ Thousand by Region/Country: 2020-2027

Table 26: Agriculture (Application) Historic Demand Patterns in US$ Thousand by Region/Country: 2012-2019

Table 27: Agriculture (Application) Market Share Shift across Key Geographies: 2012 VS 2020 VS 2027

Table 28: Healthcare & Hygiene (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 29: Healthcare & Hygiene (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2012-2019

Table 30: Healthcare & Hygiene (Application) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

Table 31: Contact Lenses (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2020-2027

Table 32: Contact Lenses (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2012-2019

Table 33: Contact Lenses (Application) Share Breakdown Review by Region/Country: 2012 VS 2020 VS 2027

Table 34: Drug Delivery (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2020-2027

Table 35: Drug Delivery (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2012-2019

Table 36: Drug Delivery (Application) Distribution of Global Sales by Region/Country: 2012 VS 2020 VS 2027

Table 37: Tissue Engineering (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2020 through 2027

Table 38: Tissue Engineering (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2012 to 2019

Table 39: Tissue Engineering (Application) Global Market Share Distribution by Region/Country for 2012, 2020, and 2027

Table 40: Other Applications (Application) Global Opportunity Assessment in US$ Thousand by Region/Country: 2020-2027

Table 41: Other Applications (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2012-2019

Table 42: Other Applications (Application) Percentage Share Breakdown of Global Sales by Region/Country: 2012 VS 2020 VS 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Table 43: United States Hydrogels Market Estimates and Projections in US$ Thousand by Raw Material: 2020 to 2027

Table 44: Hydrogels Market in the United States by Raw Material: A Historic Review in US$ Thousand for 2012-2019

Table 45: United States Hydrogels Market Share Breakdown by Raw Material: 2012 VS 2020 VS 2027

Material: 2012 VS 2020 VS 202

Table 47: Hydrogels Market in the United States by Composition: A Historic Review in US$ Thousand for 2012-2019

Table 48: United States Hydrogels Market Share Breakdown by Composition: 2012 VS 2020 VS 2027

Table 49: United States Hydrogels Latent Demand Forecasts in US$ Thousand by Application: 2020 to 2027

Table 50: Hydrogels Historic Demand Patterns in the United States by Application in US$ Thousand for 2012-2019

Table 51: Hydrogels Market Share Breakdown in the United States by Application: 2012 VS 2020 VS 2027

CANADA Table 52: Canadian Hydrogels Market Estimates and Forecasts in US$ Thousand by Raw Material: 2020 to 2027

Table 53: Canadian Hydrogels Historic Market Review by Raw Material in US$ Thousand: 2012-2019

Table 54: Hydrogels Market in Canada: Percentage Share Breakdown of Sales by Raw Material for 2012, 2020, and 2027

Table 55: Canadian Hydrogels Market Estimates and Forecasts in US$ Thousand by Composition: 2020 to 2027

Table 56: Canadian Hydrogels Historic Market Review by Composition in US$ Thousand: 2012-2019

Table 57: Hydrogels Market in Canada: Percentage Share Breakdown of Sales by Composition for 2012, 2020, and 2027

Table 58: Canadian Hydrogels Market Quantitative Demand Analysis in US$ Thousand by Application: 2020 to 2027

Table 59: Hydrogels Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2012-2019

Table 60: Canadian Hydrogels Market Share Analysis by Application: 2012 VS 2020 VS 2027

JAPAN Table 61: Japanese Market for Hydrogels: Annual Sales Estimates and Projections in US$ Thousand by Raw Material for the Period 2020-2027

Table 62: Hydrogels Market in Japan: Historic Sales Analysis in US$ Thousand by Raw Material for the Period 2012-2019

Table 63: Japanese Hydrogels Market Share Analysis by Raw Material: 2012 VS 2020 VS 2027

Table 64: Japanese Market for Hydrogels: Annual Sales Estimates and Projections in US$ Thousand by Composition for the Period 2020-2027

Table 65: Hydrogels Market in Japan: Historic Sales Analysis in US$ Thousand by Composition for the Period 2012-2019

Table 66: Japanese Hydrogels Market Share Analysis by Composition: 2012 VS 2020 VS 2027

Table 67: Japanese Demand Estimates and Forecasts for Hydrogels in US$ Thousand by Application: 2020 to 2027

Table 68: Japanese Hydrogels Market in US$ Thousand by Application: 2012-2019

Table 69: Hydrogels Market Share Shift in Japan by Application: 2012 VS 2020 VS 2027

CHINA Table 70: Chinese Hydrogels Market Growth Prospects in US$ Thousand by Raw Material for the Period 2020-2027

Table 71: Hydrogels Historic Market Analysis in China in US$ Thousand by Raw Material: 2012-2019

Table 72: Chinese Hydrogels Market by Raw Material: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 73: Chinese Hydrogels Market Growth Prospects in US$ Thousand by Composition for the Period 2020-2027

Table 74: Hydrogels Historic Market Analysis in China in US$ Thousand by Composition: 2012-2019

Table 75: Chinese Hydrogels Market by Composition: Percentage Breakdown of Sales for 2012, 2020, and 2027

Table 76: Chinese Demand for Hydrogels in US$ Thousand by Application: 2020 to 2027

Table 77: Hydrogels Market Review in China in US$ Thousand by Application: 2012-2019

Table 78: Chinese Hydrogels Market Share Breakdown by Application: 2012 VS 2020 VS 2027

EUROPE Table 79: European Hydrogels Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027

Table 80: Hydrogels Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019

Table 81: European Hydrogels Market Share Shift by Region/Country: 2012 VS 2020 VS 2027

Table 82: European Hydrogels Market Estimates and Forecasts in US$ Thousand by Raw Material: 2020-2027

Table 83: Hydrogels Market in Europe in US$ Thousand by Raw Material: A Historic Review for the Period 2012-2019

Table 84: European Hydrogels Market Share Breakdown by Raw Material: 2012 VS 2020 VS 2027

Table 85: European Hydrogels Market Estimates and Forecasts in US$ Thousand by Composition: 2020-2027

Table 86: Hydrogels Market in Europe in US$ Thousand by Composition: A Historic Review for the Period 2012-2019

Table 87: European Hydrogels Market Share Breakdown by Composition: 2012 VS 2020 VS 2027

Table 88: European Hydrogels Addressable Market Opportunity in US$ Thousand by Application: 2020-2027

Table 89: Hydrogels Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2012-2019

Table 90: European Hydrogels Market Share Analysis by Application: 2012 VS 2020 VS 2027

See the rest here:
The global market for Hydrogel is projected to reach US$15.3 billion by 2025 - GlobeNewswire

Skin Stem Cells Comments Off on The global market for Hydrogel is projected to reach US$15.3 billion by 2025 – GlobeNewswire | August 18th, 2020

An exclusive market study published by Fact.MR on the Autologous Fat Grafting market offers insights related to how the market is projected to grow over the forecast period (2019-2029). The objective of the report is to enable our readers to understand the various aspects of the Autologous Fat Grafting market and assist them to formulate impactful business strategies. Furthermore, the different factors that are expected to influence the current and future dynamics of the Autologous Fat Grafting market are discussed in the presented study.

According to the report, the Autologous Fat Grafting market is set to reach a market value of ~US$ XX by the end of 2029 and register a CAGR growth of ~XX% during the assessment period. The report offers an in-depth understanding of the Autologous Fat Grafting supply chain, value, and volume chain across the various regional markets.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=2701

Important Insights Enclosed in the Report:

The published report provides a deep understanding of the Autologous Fat Grafting market by segregating the market into different segments such as region, application, and end-use industry.

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=2701

Autologous Fat Grafting Market Segmentation

By Region

The regional analysis of the Autologous Fat Grafting market dives deep to understand the market scenario in different regions. The market size, share, and value of each regional market is analyzed and presented in the report along with informative tables and figures.

By Application

The report offers a clear picture of how the Autologous Fat Grafting is utilized in various applications. The different applications covered in the report include:

By End-Use Industry

The end-use industry assessment throws light on the consumption of the Autologous Fat Grafting across various end-use industries including:

Competition Landscape

The four leading companies that account for the consolidation of the competition landscape of autologous fat grafting market, continue to represent a whopping 80% share in the revenues. Allergan, MicroAire, Alma Lasers, and Human Med are expected to primarily maintain their strategic focus on partnerships and acquisitions with smaller yet active players. The latter are typically specialized in the development of meniscus repair systems for treating meniscal scars. With this, leading companies operating in autologous fat grafting industry, are eyeing feasibility of entry in the meniscal scars treatment landscape. Increasing strategic tie-ups among manufacturers of systems & accessories, and recognized research institutions, aim to ensure sufficient device supply and superior post-sales service.

Manufacturers in the autologous fat grafting market are also investing efforts in introducing innovative products, to enhance their market shares. For instance, in 2019, Alma Lasers (Sisram Medical) announced the availability of BeautiFill as the novel laser-based technique for fat harvesting, while leveraging autologous fat to restore the volume to body or face. As cellular therapies are increasingly being perceived as mainstream therapeutic option, there has been a surge in demand for adipose derived stem cells (ADSC), which is potentially applicable in tissue engineering and regeneration. Additionally, a growing focus of leading players on introducing advanced systems & accessories is likely to extend applicability of their offerings, leveraging untapped opportunities in the autologous fat grafting market.

For more incisive insights into the autologous fat grafting market, request for the report sample

Key Factors Shaping Autologous Fat Grafting Market

For more intelligence on the autologous fat grafting market, request for the report sample

Key Challenges Facing Autologous Fat Grafting Market

Additional Insight

Biomaterial Research to Open Doors to Multiple Opportunities

Autologous fat grafting technique continues to witness frequent technical modifications. The adoption of autologous fat grafting as a technique to augment and regenerate deficient, irradiated, and aged subcutaneous soft tissue and skin, with minimal complication rate and donor-site morbidity, has grown spectacularly over the recent past. An approach garnering research interests for its potential role in enhancing volumetric retention of fat grafts, involves insertion of autologous platelet-rich fibrin (PRF) into graft tissues. A relevant study indicates PRF as a concentrate that may enhance the outcome of fat grafting for plastic surgery procedures. This newer biomaterial with several potential advantages, such as simpler preparation with no external additive, is likely to trigger new product developments in the autologous fat grafting market.

Autologous Fat Grafting Market Research Methodology

A patented research methodology and a holistic approach form the base of the insightful information provided in the autologous fat grafting market report. This study provides detailed information about the key factors associated with the growth of autologous fat grafting market and presents a systematic breakdown of the factors shaping the progress of market. Detailed primary and secondary research has been done to offer information about the historic and prospective analysis of fat grafting industry, with emphasis on the autologous fat grafting procedure. The report on autologous fat grafting market has also gone through several validation tunnels to guarantee the uniqueness of the insights and key growth influencers, covered in the report.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=2701

Important queries addressed in the Autologous Fat Grafting market report:

Reasons to Choose Fact.MR

Read the original:
Autologous Fat Grafting Expected to Expand at a Steady CAGR through 2019 to 2029 - Scientect

Skin Stem Cells Comments Off on Autologous Fat Grafting Expected to Expand at a Steady CAGR through 2019 to 2029 – Scientect | August 18th, 2020

The global market for cell harvesting should grow from $885 million in 2018 to reach $1.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.3% for the period of 2018-2023.

Request For Report [emailprotected]https://www.trendsmarketresearch.com/report/sample/11685

Get Complete TOC with Tables and [emailprotected]https://www.trendsmarketresearch.com/report/discount/11685

<<>>https://www.trendsmarketresearch.com/report/covid-19-analysis/11685

Report Scope:

The scope of the report encompasses the major types of cell harvesting that have been used and the cell harvesting technologies that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

The report provides a summary of the market, including a market snapshot and profiles of key players in the cell harvesting market. It provides an exhaustive segmentation analysis of the market with in-depth information about each segment. The overview section of the report provides a description of market trends and market dynamics, including drivers, restraints and opportunities. it provides information about market developments and future trends that can be useful for organizations, including wholesalers and exporters. It provides market positionings of key players using yardsticks of revenue, product portfolio, and recent activities. It further includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Readers will also find historical and current market sizes and a discussion of the markets future potential. The report will help market players and new entrants make informed decisions about the production and exports of goods and services.

Report Includes:

41 data tables and 22 additional tables Description of segments and dynamics of the cell harvesting market Analyses of global market trends with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023 Characterization and quantification of market potential for cell harvesting by type of harvesting, procedure, end user, component/equipment and region A brief study and intact information about the market development, and future trends that can be useful for the organizations involved in Elaboration on the influence of government regulations, current technology, and the economic factors that will shape the future marketplace Key patents analysis and new product developments in cell harvesting market Detailed profiles of major companies of the industry, including Becton, Dickinson and Co., Corning, Inc., Fluidigm Corp., General Electric Co., Perkinelmer, Inc., and Thermo Fisher Scientific, Inc.

Summary

Stem cells are unspecialized cells that have the ability to divide indefinitely and produce specialized cells. The appropriate physiological and experimental conditions provided to the unspecialized cells give rise to certain specialized cells, including nerve cells, heart muscle cells and blood cells. Stem cells can divide and renew themselves over long periods of time. These cells are extensively found in multicellular organisms, wherein mammals, there are two types of stem cells embryonic stem cells and adult stemcells. Embryonic stem cells are derived from a human embryo four or five days old that is in the blastocyst phase of development. Adult stem cells grow after the development of the embryo and are found in tissues such as bone marrow, brain, blood vessels, blood, skin, skeletal muscles and liver. Stemcell culture is the process of harvesting the exosomes and molecules released by the stem cells for the development of therapeuticsfor chronic diseases such as cancer and diabetes.

The process is widely used in biomedical applications such as therapy, diagnosis and biological drug production. The global cell harvesting market is likely to witness a growth rate of REDACTED during the forecast period of 2018-2023.The value of global cell harvesting market was REDACTED in 2017 and is projected to reach REDACTED by 2023. Market growth is attributed to factors such as increasing R&D spending in cell-based research,the introduction of 3D cell culture technology, increasing government funding, and the growing prevalence of chronic diseases such as cancer and diabetes.

The growing incidence and prevalence of cancer is seen as one of the major factors contributing to the growth of the global cell harvesting market. According to the World Health Organization (WHO), cancer is the second-leading cause of mortality globally and was responsible for an estimated 9.6 million deaths in 2018. Therefore, there is an increasing need for effective cancer treatment solutions globally. Cell harvesting is the preferred method used in cancer cell-related studies including cancer cell databases (cancer cell lines), and other analyses and drug discovery in a microenvironment.

The rising prevalence of such chronic diseases has led governments to provide R&D funding to research institutes and biotechnology companies to develop advanced therapeutics. Various 3D cell culture technologies have been developed by researchers and biotechnology companies such as Lonza Group and Thermo Fischer Scientific for research applications such as cancer drug discovery. The application of cell culture in cancer research is leading to more predictive models for research, drug discovery and regenerative medicine applications.

Platelet-rich plasma (PRP) therapy, a new biotechnology solution that has a heightened interest among researchers in tissue engineering and cell-based therapies, has various applications in the treatment of tissue healing in tendinopathy, osteoarthritis and muscle injury. It has been conventionally employed in orthopedics, maxillofacial surgery, periodontal therapy and sports medicines. PRP therapy can be used in the treatment of fat grafting, acne scars, and hair regrowth.

Major factors driving market growth include increasing healthcare costs and the high rate of adoption for modern medicines in emerging economies such as China and India. It has been estimated that India will witness a CAGR of REDACTED in the cell harvesting market during the forecast period. The active participation of foreign pharmaceutical companies has tapped the Indian healthcare sector with a series of partnerships and mergers and acquisitions, which in turn is positively impacting the growth of the market in this region.

Consistent development and clinical trials for stem cell therapies, plus contribution from the government and private sectors through investments and cohesive reimbursement policies in the development of cancer biomarkers, is further fueling market growth. InSweden, a research team at Lund University has developed a device to collect fluid and harvest stem mesenchymal stem cells (MSCs). The device is developed with 3D-printed bio-inert plastics which, when used by doctors, can result in the safe extraction of fluids (medical waste) from the patients body. The liquid is then passed through a gauze filter for purifying thoroughly and MSCs are separated from the fluid by centrifugation and are grown in culture.

Go here to see the original:
Cell Harvesting Market Market Will Grow At CAGR During 2018-2023 Global Evaluation By Trends, Proportions, Share, Swot, And Key Developments -...

Skin Stem Cells Comments Off on Cell Harvesting Market Market Will Grow At CAGR During 2018-2023 Global Evaluation By Trends, Proportions, Share, Swot, And Key Developments -… | August 18th, 2020

By the time this column is published, the one-year anniversary of my lifesaving stem cell transplant will have come and gone. But as I sit here sweating away in the thick humidity of a rare August heat wave, and as the sun sets upon my little garden in the boroughs of North London, I cant help but bask in this moment of reflection and humble appreciation.

An entire year has come and gone, just like that. Time is such a strange, bizarre phenomenon. It feels as if it has passed by in a blur a simple snap of my fingers and yet so much has transpired. So much has unfurled and unfolded, fallen apart and come together, all in just 12 tiny months.

One year ago today, I was lying in a sterile hospital bed with a drip attached to my veins. I was puffy, exhausted, and frail from the chemicals seeping into my blood. I had no immune system and was days away from having my sisters stem cells infused into my bloodstream, where they would collectively begin to regenerate an entirely new immune system.

A year ago, I could barely walk because I was so weak. I had no connection to my body other than distrust. I was small, sad, tired, and full of grief and heartache. A year ago, the world was painfully heavy and dark. Now, as I sit here staring at the trees in my backyard and watching the sun pour through the gaps in the branches, painting the leaves a brilliant verdant green, I see so much light in the world its almost blinding.

I just returned from a weekend in the English countryside with some of my best friends. We stayed in a house beside the sea on the coast of Cornwall. The sun was warm, and the world felt like it was washed in a soft, tangerine glow. I cant remember the last time I have laughed so much. I felt wonderfully alive, radiating with joy at the sheer beauty of all the small, simple things. The tiny white and yellow daisies we picked from the bushes on the side of the road, the perfect flapping of a butterflys delicate wings, the sound of my friends laughter, the lightness of being, the magnificence of loving, and being loved in return.

This anniversary is deeply significant to me because it symbolizes just how far I have come. If only a year ago, lying in that hospital bed, Id had a crystal ball and could have seen into the future and understood that everything really would be OK. If only I could have seen my strong, able body, my mop of unruly blond curls, my happy, overflowing heart. Back then, it felt like my life was falling apart. Now, despite all the unexpected twists and turns and challenges of this tumultuous year, the disparity between where I was then and where I am now is not lost on me.

I think thats the greatest gift Ive gained from the long periods of sickness and convalescence Ive endured understanding the true value of being healthy.

Nothing can take that lesson from me now, and for that, Im deeply grateful. Ill always be able to look back and recall exactly what it felt like to lie in that ward, watching the clock, wishing time would pass, desperately longing to feel better, to just feel like myself again.

Health and time are the two things we take for granted the most, yet they are the greatest gifts we will ever have.

Despite how quickly this year has passed, it also has been filled with nothing but time. Time to sit and reflect. Time inside. Time alone. Time apart from loved ones. Its been tough, painful, and full of missing. But its also been deeply healing. I have watched as my body has transformed from a weak, thin, pale, depleted shell of skin and bones to a strong, tanned, healthy, muscular machine. I have watched the pigment return to my skin, the smile return to my cheeks, the sparkle return to my eyes. I never could have imagined the progress I would make in a year, and Im so deeply proud of myself for persevering through those dark, drawn-out days.

For anyone facing the eye of the storm now, or fresh off the boat of treatment, I want you to know that it does get better. If only I could whisper in the ear of that scared and sick girl and tell her that everything will be OK. That things wont stay dark forever. To hold on, theres so much more to come.

What a year, what a life.

***

Note: Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Lymphoma News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to lymphoma.

Read the original:
Reflections on My 'Re-birthday' and the Past Year of Recovery - Lymphoma News Today

Skin Stem Cells Comments Off on Reflections on My ‘Re-birthday’ and the Past Year of Recovery – Lymphoma News Today | August 17th, 2020

As the on-going COVID-19 pandemic continues we are facing a huge healthcare crisis. Globally the pandemic has accelerated or rather decelerated the entire human population into the confines. Work from home, social shielding and discreet outdoor ventures has not only disrupted our emotional well-being but has also drastically affected our physical health. As people are confined to their homes with reduced physical activity there is rapid bone resorption (loss) as muscles and bones are not getting adequate stimulation. Also lack of exposure to sun during the pandemic has critically affected vitamin D levels in our body. People are frequently feeling tired with lack of energy and strength. Everyone needs to be cautious about the health of their bones as much as their other needs. Bones support us and allow us to be mobile. Bone health is always a priority and we always tend to overlook it. Bone density problem is a silent manifestation and could lead to a major medical issue over a period of time. While osteoporosis onsets with age among men & women, women face the brunt a little earlier, like from their 30s. Well-versed with the situation and to avoid unnecessary bones issues, let us now take a look at some measures that can take care of your bones during the pandemic.Eat a well-balanced diet rich in calcium and vitamin DGood sources of calcium include low-fat dairy products, green leafy veggies and dry fruits. Good sources of vitamin D include fortified cereals, egg yolks, saltwater fish, liver and milk. Calcium and vitamin D work together to protect your bones - calcium helps to build and maintain bones; while vitamin D helps your body to effectively absorb calcium.

Get exposure to sunlight to make enough vitamin DRegular sun exposure is the most natural way to get enough vitamin D. The sun's ultraviolet B (UVB) rays hit cholesterol in the skin cells, providing the energy for vitamin D synthesis. Vitamin D has a significant role in calcium homeostasis and metabolism.

As per pan-India study the best time to get exposed to the sun is between 11 am and 1 pm since the wavelength of ultraviolet B (UVB) rays is 290-320nm during this period which is essential for skin to make vitamin D.

Get plenty of physical activityLike muscles, bones become stronger with exercise. The best exercises for healthy bones are strength-building and weight-bearing exercise like walking, climbing stairs, lifting weights and dancing. Try to get 30 minutes of exercise each day.

Strength-building and weight-bearing exercise provides stimulation to bone cells and helps to increased bone mineral density and bone size thus reduced the risk of osteoporosis.

Live a healthy lifestyle

Visit link:
What do we need to know about our bone health during this pandemic - Times of India

Skin Stem Cells Comments Off on What do we need to know about our bone health during this pandemic – Times of India | August 17th, 2020

What is testicular cancer?

Testicular cancer arises from the testes (a part of the male reproductive system). The testicles are responsible for the production of male sex hormones and sperm for reproduction. They are located within the scrotum, a loose bag of skin below the penis. Testicular cancer is the most common type of cancer occurring in males in the US between the ages of 15 and 35.

Testicular cancer can be aggressive and grow and spread rapidly. However, this cancer is highly treatable even after it spreads. Hence, the prognosis for men with testicular cancer is good. Studies have shown that the risk of dying from testicular cancer is about1 in 5,000.

How is testicular cancer treated?

The treatment may involve one or a combination of multiple treatment modalities, which depends on the extent of the disease.

The treatment options include

What causes testicular cancer?

The exact cause of testicular cancer is unknown. Some factors increase the risk of testicular cancer, including

What are the warning signs of testicular cancer?

The initial signs and symptoms of testicular cancer include

What are the types of testicular cancer?

Most testicular cancers are germ cell (cells that produce sperm) tumors. There are two main types of testicular cancer, seminomas and nonseminomas.

How is testicular cancer diagnosed?

Medically Reviewed on 8/13/2020

References

Medscape

American Cancer Society

Medline

Follow this link:
What Are the Five Warning Signs of Testicular Cancer? - MedicineNet

Skin Stem Cells Comments Off on What Are the Five Warning Signs of Testicular Cancer? – MedicineNet | August 16th, 2020

Mitochondria are small organelles that provide the energy critical for each cell in our body, in particular in the high fuel-consuming brain. In this week's edition ofScience, a Belgian team of researchers led by Pierre Vanderhaeghen (VIB-KU Leuven, ULB) finds that mitochondria also regulate a key event during brain development: how neural stem cells become nerve cells. Mitochondria influence this cell fate switch during a precise period that is twice as long in humans compared to mice. The seminal findings highlight an unexpected function for mitochondria that may help explain how humans developed a bigger brain during evolution, and how mitochondrial defects lead to neurodevelopmental diseases.

Our brains are made up of billions of incredibly diverse neurons. They first arise in the developing brain when stem cells stop self-renewing and differentiate into a particular type of neuron. This process, called neurogenesis, is precisely regulated to give rise to the enormous complex structure that is our brain. It is thought that small differences in the way neural stem cells generate neurons are at the origin of the dramatic increase in the size and complexity of our brain.

To gain insight in this complex process, prof. Pierre Vanderhaeghen (VIB-KU Leuven, ULB) and his colleagues examined the mitochondria, small organelles that provide energy in every cell in the body, including the developing brain.

"Diseases caused by defects in mitochondria lead to developmental problems in many organs, in particular the brain," explains Vanderhaeghen, a specialist in stem cell and developmental neurobiology. "We used to think that this was related to the crucial function of mitochondria to provide energy to the cells, but this is only part of the story: recent work in stem cells suggests that mitochondria have a direct influence on organ development. We have tested whether and how this could be the case in the brain."

Ryohei Iwata, a postdoctoral researcher in the Vanderhaeghen lab, developed a new method to watch mitochondria in great detail as the neural stem cells are 'caught in the act' to become neurons. "We found that shortly after stem cells divide, the mitochondria in daughter cells destined to self-renew will fuse, while those in daughter cells that become neurons show high levels of fission instead," says Ryohei Iwata.

But this was not just a coincidence: indeed, the researchers could show that increased mitochondrial fission in fact promotes differentiation to a neuronal fate, while mitochondrial fusion after mitosis redirects daughter cells towards self-renewal.

"We found that the influence of mitochondrial dynamics on cell fate choice is limited to a very specific time window, right after cell division," says Pierre Casimir, a PhD student in Vanderhaeghen's lab. "Interestingly, the restricted time window is twice as long in humans compared to mice."

"Previous findings were primarily focused on fate decision of neural stem cells before they divide, but our data reveal that cell fate can be influenced for a much longer period, even after neural stem cell division," says Vanderhaeghen. This may have interesting implications in the emerging field of cell reprogramming, where scientists try to convert non-neuronal cells directly in neuronal cells for therapeutic purposes for instance.

"Since this period of plasticity is much longer in human cells compared to mouse cells, it is tempting to speculate that it contributes to the increased self-renewal capacity of human progenitor cells, and thus to the uniquely developed brain and cognitive abilities of our species. It is fascinating to think that mitochondria, small organelles that have evolved in cells more than a billion years ago, might have contributed to the recent evolution of the human brain."

Reference:Iwata, R., Casimir, P., & Vanderhaeghen, P. (2020). Mitochondrial dynamics in postmitotic cells regulate neurogenesis. Science, 369(6505), 858862. https://doi.org/10.1126/science.aba9760

Link:
To Become a Nerve Cell, Timing Is of the Essence - Technology Networks

Skin Stem Cells Comments Off on To Become a Nerve Cell, Timing Is of the Essence – Technology Networks | August 15th, 2020

Efforts to get the two to breed had not worked.

He was the equivalent of a 70-year-old man, so of course you dont expect the sperm to be all that good, said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysias rhinos.

It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this.

ACROSS THE BORDER

Indonesias environment ministry disputed accusations of cross-border rivalry as a reason why Malaysias rhinos died out, saying talks continue on ways to work with conservationists in the neighboring southeast Asian nation.

Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country, said Indra Exploitasia, the ministrys director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

Link:
Scientists hope to bring Malaysian rhinoceros back from extinction with stem cell technology - National Post

Skin Stem Cells Comments Off on Scientists hope to bring Malaysian rhinoceros back from extinction with stem cell technology – National Post | August 15th, 2020

Image: Steve Wrubel/Parfums Christian Dior By Chloe Pek August 14, 2020

The beauty expert counts Bella Hadid and Kim Kardashian amongst her clientele

Sign up for our newsletters to get all our top stories delivered.

You've Successfully Subscribed

When it comes to facial massages, celebrity facialist Joanna Czech has that magic touch. Counting Hollywood and runway bigwigs like Bella Hadid, Kim Kardashian, Jennifer Aniston, Cate Blanchett, Kate Winslet, Liam Neeson and more amongst her star-studded list of clients, Joannas skincare treatments are highly coveted internationally.

Now, the skincare expert is adding another credential to her portfoliojoining the House of Dior as a skincare ambassador and lending her expertise in developing the Dior skincare techniques international training.

In an interview via Zoom, Czech told us she had her reservations about joining Dior Skincare at first. I mean, theyre famous for make-up and fashion. I couldnt put my name next to fashion skincareIm very particular about that. Then, I heard about how the Capture Totale range stimulates cell energy, so that changed everything and my skin as well.

Czech, who originally planned to go to medical school in her schooling years, fell in love with skincare when she enrolled in the Aesthetics Institute and never looked back. However, she has remained inquisitive and fascinated with science. This is evident from her holistic approach to beauty, which combines both traditional techniques and cutting-edge technology.

See also: The Best Beauty Launches In August 2020

Adenosine triphosphate (ATP, the main carrier of energy for cellular activities) is responsible for the very first mitosis of cells. It is human physiology that production of ATP drastically drops at around seven years old, and the energy keeps slowing down. So any treatment or product that would stimulate cell energy is fascinating to me.

Culminated from Diors decades-long research into stem cells, the Capture Totale line is infused with a regenerative floral complex of Madagascan longozo, Chinese peony, white lily, and Chinese jasmine, which help to re-energise stem cells rather than replenish them.

Dont believe a product that says it contains stem cells because the stem cells are not alive within the product. Only stem cells that are directly re-injectedand most likely come from your bone marrowworks, Joanna explained, debunking one of the most popular beauty fads in recent years.

With the expert on the line, we took the opportunity to ask our burning questions about maskneand skincare misconceptions.

What is a skincare philosophy that you live by?

Respect, support and protect. This goes for skincare, how we treat ourselves and others.

Your all-time favourite Dior Skincare product and why?

The Capture Totale C.E.L.L. Energy Super Potent Serum because it contains the most concentrated version of the cell energising complex and acetylated hyaluronic acid. It creates hydrated, plump and radiant skin. If you are consistent, you see results in days. My skin has never looked better.

A common skincare mistake many people make?

In my opinion, its using toner. Thats a misconception because still, many people use a toner as the second step of cleansing as opposed to the first step of treating the skin, and this is from my experience of talking with clients.

They put toner or micellar water on a cotton pad and they keep wiping and seeing more make-up. If you see more make-up on your cotton pad, that means you need to go back into washing.

Toner is very often misunderstood or skipped, and it shouldnt be. I cant imagine, for instance, applying a serum on my face without applying toner first. There is no way the efficacy of the product will be the same if you have not applied a toner. Depending on the toner, they offer hydration and sometimes micro-exfoliation, but mainly they are used to maintain the pH of the skin. The optimal pH for our skin is 5.5, and many factors from our diet to lifestyle, and even washing our face can throw the skins pH off the scale, so it's very important to balance it back.

See also: Lancme's Celebrity Make-Up Artist Lisa Eldridge & Neelofa Share 5 Beauty Tips

With face masks becoming part of everyday life, maskne has become a real problem. How can we prevent these breakouts?

When you wear a mask, it creates a micro-climate and we keep breathing carbon dioxide back and forth, so there is not enough of anti-bacterial oxygen getting into the skin. There is sometimes too much moisture happening, so we will get super hydrated initially, and then get quite dehydrated right after. Thats when you will experience eczema and redness.

What I recommend is keeping the skin as clean as possible before wearing the mask, with just a balancing toner, and protecting balm or healing ointments to lubricate areas where the mask could potentially irritate the skin. Very often, its on the nose bridge, as well as on the side and behind the ears.

For less reactivity, I wouldnt go through with the whole routine, but if you have to, I would advise starting your routine earlier so the products are on your skin for at least 30-40 minutes. If you will be stepping out shortly, reduce the routine and skip some steps. But no matter what, never forget about your SPF because the friction of the mask could also get rid of our stratum corneum and create little scabs, causing discolourations.

Then, as soon as you arrive home, take the mask off, wash your face, and again balance your skin with toner and use your serums.

What are your tips for soothing breakouts or eczema caused by wearing masks?

Even with microscopic breakouts, I would continue using any product that is hydrating because sometimes we misunderstand we have a breakout and then we try to use benzoyl peroxide, or everything that is dehydrating. No, your skin would be producing even more sebum. So keep hydrating your skin with soothing ingredients like colostrum and hyaluronic acid.

Your skincare routine?

My morning routine is very brief: cleanser, toner, a serum and then there is moisturiser. For my night time routine, my very first step is getting into the shower when I get home. I begin with massaging my body with my shower gel and silicone gloves under the shower, then I apply products like multi-vitamin oils and sometimes micro-exfoliating toners all over my body.

Then, I go to my face. I usually dont wear any make-up, so I start right away with my cleanser with some massaging movements and I remove it with a linen washcloth, followed by a toner. My favourite way of applying toner is the sponge techniqueinitially, you spread the product on your face, and then you press and release. When you press, your skin microscopically opens and when you release, the skin grasps whatever is on the surface.

After the toner, I use my serum. Ive been using the Capture Totale C.E.L.L. Energy Super Potent Serum since September. If you have weaker areas like forehead lines and nasolabial folds, these are the areas I would concentrate longer on, followed by an eye cream and moisturiser. Thats usually my five-step basic routine.

About twice a week, I do facial masks, one of those quick ones because Im the kind of New Yorker who only has five seconds for myself. But no matter how busy or tired I am at night, I would never forget about my skincare routine. Your skin is 60 per cent more potent to absorb everything during relaxation and rejuvenation time. So if you dont take care of your skin at night, you might as well forget doing anything in the morning. Twenty-five per cent of our immune system is within our skin, and we can improve that percentage of our health with products chosen for your skin condition and consistent skincare.

See also: Sulwhasoo's Ginseng To Achieve Skin As Flawless As South Korean Superstar Song Hye Kyo's

You work with many notable clientswhats the most common skincare problem celebrities deal with and treatments that they request for?

Celebrities have exactly the same problems as we do. The only one little difference is that celebrities tend to wear more make-up and more often than some of us, usually under the heat of theatrical or film lights, so they need a lot of hydration and rebalancing. Ive been called to the movie set many times to help soothe their skin with algae masks, or any cooling and hydrating treatments.

Their needs are equal to ours. They want to work on their facial contours and ensure their skin is as evenly textured as possible so their makeup looks perfect, so I would offer some mild exfoliation, perhaps micro-currents for targeted muscle stimulation, and maybe manual massaging to stimulate blood flow to create the sort of rosy healthy oxygenated looking skin. Many people call it a red carpet facial but I call them ordinary facial because every woman wants the samesmooth hydrated skin with nice cheekbones, beautiful jawlines, and thats what really works.

See also: Beauty Talk With Aznita Azman, Founder Of Nita Cosmetics

The rest is here:
Dior Skincare Ambassador Joanna Czech On Her Self-Care Routine And How To Prevent Maskne - Tatler Malaysia

Skin Stem Cells Comments Off on Dior Skincare Ambassador Joanna Czech On Her Self-Care Routine And How To Prevent Maskne – Tatler Malaysia | August 15th, 2020

Some skin, eggs and tissue samples are all that remain of Malaysia's last rhino, Iman, who died last November after years of failed breeding attempts.

Now scientists are pinning their hopes on experimental stem cell technology to bring back the Malaysian variant of the Sumatran rhinoceros, making use of cells from Iman and two other dead rhinos.

"I'm very confident," molecular biologist Muhammad Lokman Md Isa told Reuters in his laboratory at the International Islamic University of Malaysia.

"If everything is functioning, works well and everybody supports us, it's not impossible."

The smallest among the world's rhinos, the Sumatran species was declared extinct in the wild in Malaysia in 2015. Once it had roamed across Asia, but hunting and forest clearance reduced its numbers to just 80 in neighboringIndonesia.

Iman, 25, died in a nature reserve on Borneo island, following massive blood loss caused by uterine tumors, within six months of the death of Malaysia's last male rhino, Tam.

Efforts to get the two to breed had not worked.

"He was the equivalent of a 70-year-old man, so of course you don't expect the sperm to be all that good," said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysia's rhinos.

"It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos inIndonesia. But right till today,Indonesiais still not keen on this."

Across the border

Indonesia's environment ministry disputed accusations of cross-border rivalry as a reason why Malaysia's rhinos died out, saying talks continue on ways to work with conservationists in the neighboring southeast Asian nation.

"Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country," said Indra Exploitasia, the ministry's director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embryonic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

And even if it worked, the animals' lack of genetic diversity could pose a threat to long-term survival, Galli told Reuters.

Indonesian scientist Arief Boediono is among those helping in Malaysia, hoping success will provide lessons to help his country's rhinos.

"It may take five, 10, 20 years, I don't know," Arief added. "But there has already been some success involving lab rats in Japan, so that means there is a chance."

Japanese researchers have grown teeth and organs such as pancreas and kidneys using embryonic stem cells from rats and mice in efforts to grow replacement human organs.

For now, however, Iman's hide will be stuffed and put on display alongside Tam in a Borneo museum.

Your premium period will expire in 0 day(s)

Subscribe to get unlimited access Get 50% off now

See original here:
Back from the dead? Stem cells give hope for revival of Malaysia's extinct rhinos - The Jakarta Post - Jakarta Post

Skin Stem Cells Comments Off on Back from the dead? Stem cells give hope for revival of Malaysia’s extinct rhinos – The Jakarta Post – Jakarta Post | August 13th, 2020

Aug 13 (Reuters) - Every week, Reuters journalists produce scores of multimedia features and human-interest stories from around the world.

Below are some engaging stories selected by our editors, as well as explanatory context and background on world headlines. For a full schedule of news and events, please go to our editorial calendar on Reuters Connect here

Baby George, born amid Beirut blast, is light in the darkness

BEIRUT, Aug 12 - Stepping into the delivery room where his wife Emmanuelle was about to give birth, Edmond Khnaisser meant to capture their sons first moments on camera. Instead, he recorded the instant the biggest blast in Lebanons history sent windows crashing onto the hospital bed. (LEBANON-SECURITY/BLAST-BABY (TV, PIX), moved, 401 words)

Squeegee selfies: Tel Aviv tower-washer is rising TikTok star

TEL AVIV, Aug 11 - Twirling to hip hop over chasms of steel and glass, soapy squeegee in one hand and a smartphone in the other, Noa Toledo is an Israeli social media star who aims to encourage other women to take on her traditionally male-dominated job. (ISRAEL-SOCIALMEDIA/WINDOW WASHER (TV, PIX), moved, 155 words)

From carats to peanuts: how a pandemic upended the global diamond industry

JOHANNESBURG/MUMBAI, Aug 12 - As the coronavirus pandemic shuttered mines from Lesotho to Canada and disrupted supply chains, Rajen Patel swapped diamond polishing for peanut farming. (HEALTH-CORONAVIRUS/DIAMONDS (PIX, GRAPHICS), by Helen Reid, Tanisha Heiberg and Rajendra Jadhav, 828 words)

Raphael did a nose-job in self-portrait, face reconstruction suggests

ROME, Aug 11 - Raphael probably didnt like his nose, and replaced it with an idealised version in his famous self-portrait. (ARTS-ITALY/RAPHAEL (PIX, TV), by Philip Pullella, 399 words)

Back from the dead? Stem cells give hope for revival of Malaysias extinct rhinos

KUANTAN, Malaysia, Aug 12 - Some skin, eggs and tissue samples are all that remain of Malaysias last rhino, Iman, who died last November after years of failed breeding attempts. (MALAYSIA-WILDLIFE/RHINO (TV, PIX), by Joseph Sipalan, 517 words)

Dream destination cafes offer taste of paradise in blockaded Gaza strip

GAZA, Aug 11 - Mediterranean waves crash below patrons snacking on freshly-caught fish at the Maldive Gaza cafe, offering a glimpse of paradise to Palestinians confined to the blockaded strip. (PALESTINIANS-GAZA/MALDIVES (TV, PIX), by Nidal al-Mughrabi, 207 words)

Virtually identical: Grounded Japanese try foreign holidays with a difference

TOKYO, Aug 12 - Japanese businessman Katsuo Inoue chose Italy for this years summer vacation, and he enjoyed the trimmings of a business class cabin and soaked up the sights of Florence and Rome - without ever leaving Tokyo. (HEALTH CORONAVIRUS/JAPAN-VR TRAVEL (TV, PIX), by Akira Tomoshige, 296 words)

For the art collector with everything, the $1.5 million COVID mask

MOTZA, Israel, Aug 12 - Art rather than ostentation is the rationale behind the worlds most expensive coronavirus mask, say the Israeli jewellers who are crafting the $1.5 million object for an unnamed U.S.-based client. (HEALTH-CORONAVIRUS/ISRAEL-MASK (TV, PIX), moved, 234 words)

Coping with campus coronavirus: U.S. fraternities, sororities give it the old college try

MADISON, Wisconsin, Aug 12 - Sixteen gallons of hand sanitizer sat in the foyer of the Alpha Epsilon Phi sorority house at the University of Wisconsin as house mother Karen Mullis reconfigured tables in the dining room to maintain social distancing. (HEALTH-CORONAVIRUS/FRATERNITIES-SORORITIES (PIX, GRAPHIC), by Brendan OBrien, 754 words)

Some U.S. colleges stick to in-person reopening in pandemic despite doubts, pushback

Aug 11 - Many U.S. universities are revamping campuses to resume in-person classes despite COVID-19, drawing criticism from some college town residents and critics who say schools are putting profits before public safety. (HEALTH-CORONAVIRUS/UNIVERSITIES (PIX, TV, GRAPHIC), by Jan Wolfe and Catherine Koppel, 729 words)

EXPLAINER-The U.S. push to extend U.N. arms embargo on Iran

Where Biden and Trump stand on key issues (tmsnrt.rs/3iDd4YG)

FACTBOX-Who is speaking at the Democratic National Convention - and why

NEWSMAKER-How Kamala Harris found the political identity that had eluded her

FACTBOX-Political crisis unfolds in Belarus after presidential vote

EXPLAINER-Microsofts TikTok bid spotlights Windows makers history with China

FACTBOX-Who is Jimmy Lai, the media tycoon arrested in Hong Kong?

FACTBOX-How financial firms in Hong Kong may be affected by U.S. sanctions

UNDERSTANDING COVID-19

EXPLAINER-When will a coronavirus vaccine be ready?

FACTBOX-World reaction to Russias COVID-19 vaccine

FACTBOX-U.S., UK spend billions to take lead in securing coronavirus vaccines

GRAPHIC-U.S. COVID-19 deaths drop for first time in four weeks (tmsnrt.rs/2WTOZDR)

The Lifeline Pipeline: the drugs, tests and tactics that may conquer coronavirus (reut.rs/3bhMUaE)

Coronavirus and the global economy (tmsnrt.rs/3cg7OXF)

The new normal: How far is far enough? (tmsnrt.rs/3dKqnnn)

Prominent people diagnosed with COVID-19

Global tracker (tmsnrt.rs/2W82n73)

U.S. tracker (tmsnrt.rs/2ySIhG0) (Compiled by Leela de Kretser, Patrick Enright and Tiffany Wu)

Follow this link:
IN CASE YOU MISSED ITSchedule of Reuters features from this week - Reuters

Skin Stem Cells Comments Off on IN CASE YOU MISSED ITSchedule of Reuters features from this week – Reuters | August 13th, 2020

Is it acne, a rash or maybe something more serious? Skin disorders can vary in both symptoms and severity. Some skin conditions are minor, some are serious but treatable, and others, like skin cancer, can be life-threatening. Here are 18 common (and a few less common) skin conditions with photos to help you ID them. Remember to always reach out to your physician for a proper diagnosis and treatment.

Acne | Actinic keratosis | Basal cell carcinoma | Blisters | Carbuncle | Cellulitis | Chicken pox | Cold sores | Contact dermatitis | Eczema | Hives | Latex allergy | Lupus | Measles | Melanoma | Psoriasis | Rosacea | Squamous cell carcinoma

Suffering from acne? Youre not alone. Acne is the most common condition dermatologists treat 40 to 50 million Americans struggle with acne at any given time.

Acne can show up almost anywhere on the skin as blackheads, papules and pustules or pimples, cysts and nodules

Acne starts when dead skin cells dont shed properly and clog your pores.

Some acne can be treated with over-the-counter products, while others require professional help, including prescription medication and treatments.

Read more about acne and how to treat it.

These precancerous lesions often appear as rough spots on the skin. Actinic keratosis is common, but if left untreated it can turn into squamous cell carcinoma.

The appearance of actinic keratosis can vary from bumps that look like pimples or acne to rough lesions that are red, pink or gray.

When cells in the skin called keratinocytes are damaged by UV rays, it can cause actinic keratosis.

While not always necessary, treatments may include removal of the actinic keratosis with liquid nitrogen, chemical peels, scraping or other therapies.

Read more about actinic keratosis and how to treat it.

Basal cell carcinoma is the most common type of skin cancer. It affects approximately 2.6 million people in the U.S. each year. Do you know how to spot it?

Basal cell carcinoma is much more common in people who have light skin. Symptoms tend to be the same color as the skin or pink. Its important to look for any changes in your skin.

Exposure from ultraviolet rays (UV) from the sun or indoor tanning is a primary cause of basal cell carcinoma.

Your dermatologist may be able to remove a basal cell carcinoma tumor when doing a biopsy. Sometimes a Mohs surgery is recommended.

Read more about basal cell carcinoma and how to spot it.

A common skin condition, most people develop blisters once in a while.

Blisters are small, painful sacs of fluid.

Blisters can be caused by friction, such as by a shoe rubbing against the skin, or by sunburns, heat or skin diseases.

Blisters tend to heal on their own, but a blister can be drained if its too painful.

Read more about blisters and how to treat them.

Sometimes confused with a spider bite, a carbuncle is a group of boils that stem from an infection of the skin and are connected to each other.

Red, tender bumps, or boils, that contain pus are signs of a carbuncle. Carbuncles can eventually rupture, and pus will leak out of them.

A bacterial infection, such as Staphylococcus aureus, is often the cause of a carbuncle.

If a carbuncle is small, you may be able to treat it at home with warm compresses and bandages. Otherwise, your dermatologist can make an incision to drain the pus.

Read more about carbuncles and how to treat them.

Cellulitis is an infection of the skin in which the skin becomes red and swollen. It typically occurs after you get a cut or wound.

When you have cellulitis, an area of your skin often on one of your legs becomes red, swollen, warm and possibly painful.

Cellulitis can be caused by two different types of bacteria: streptococcus (aka strep) or staphylococcus (aka staph).

Antibiotics like penicillin, cephalosporin or erythromycin are normally used to treat cellulitis.

Read more about cellulitis and how to treat it.

Also called varicella, this highly contagious disease mostly strikes children.

A fever may precede it, but the unique chicken pox rash appears on the skin with itchy blisters that look like lots of little dew drops.

The varicella-zoster virus (VZV) causes chicken pox as well as shingles. Its unlikely to get chicken pox if youve had the chicken pox vaccine.

The best treatment for chicken pox is prevention through vaccination. An early case of chicken pox may be treated with antiviral drugs. Other remedies can be used to ease symptoms.

Read more about chicken pox and how to treat it.

Trending stories,celebrity news and all the best of TODAY.

Also known as fever blisters, cold sores are blisters, or clusters of blisters, that appear on your lips or near your mouth.

Symptoms of cold sores can vary. The sores may start with a tingling, burning or other sensation, then break open and scab over.

Cold sores are caused by the herpes simplex virus. Outbreaks are triggered by stress, fatigue, illness and other factors.

Read more about cold sores and how to treat them.

Almost everyone gets contact dermatitis at some point. There are two main types of contact dermatitis allergic and irritant. Both trigger a rash.

Symptoms of allergic contact dermatitis may include itching, rash, dryness and other symptoms. Cracked, itchy, chapped skin with sores may be signs of irritant contact dermatitis.

Contact dermatitis is caused by something that touches your skin like poison ivy, nickel, fragrances, latex or other irritants and triggers a rash.

The best treatment for contact dermatitis is to avoid whatever it is that triggers your rash. Beyond that, your dermatologist may also recommend antihistamine pills, moisturizers or topical steroids.

Read more about contact dermatitis and how to treat it.

Eczema is a condition that causes red, itchy patches on the skin. It often starts at a young age often people with eczema get it when they're babies.

Eczema is almost always itchy, but otherwise symptoms can vary from person to person. Skin infected with eczema can be dry, dark, scaly, swollen or oozing.

Eczema may be caused by an overactive immune system, but its not entirely clear what causes the condition.

There is no cure for eczema, but symptoms can be managed with medications and other therapies.

Read more about eczema and how to treat it

The onset of hives can be mysterious, and though hives usually go away in less than 24 hours, new ones can repeatedly appear.

Hives appear on the skin as slightly swollen, raised pink or red patches. You may have one hive, a group of hives that may be separate or connected together.

Its difficult to pinpoint the cause of hives, but there are many triggers that can cause hives, from insect bites and allergic reactions to medication, stress and heat.

The go-to treatment for hives is usually antihistamines.

Read more about hives and how to treat them.

People with an allergy to latex are allergic to a protein found in the sap of the Brazilian rubber tree.

Different symptoms appear with different types of latex allergies. One type causes a rash on the skin; another can cause anaphylaxis, which can result in a swelling of the airways and difficulty breathing.

When your immune system reacts as though latex is a harmful substance, it causes an allergic reaction to latex.

Since theres no cure for latex allergies, your best bet is to avoid coming into contact with latex.

Read more about latex allergy and how to treat it.

An autoimmune disease that causes pain and inflammation, lupus can affect your skin, as well as your kidneys, heart, joints and lungs.

A red butterfly-shaped rash that appears on the nose and cheeks is one common sign of lupus, but symptoms of lupus will vary, depending on the type of lupus you have.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about lupus and how to treat it.

Also known as rubeola, measles is a contagious and potentially deadly disease that usually strikes children.

Beyond the signifying red, spotted rash, measles may also be accompanied by a fever, cough, runny nose and other symptoms.

A virus that infects the respiratory tract and spreads throughout the body causes measles. Its one of the most contagious diseases.

The best treatment is prevention through a vaccine. Otherwise, high doses of vitamin A, bed rest and medications to reduce pain and fever may help.

Read more about measles and how to treat it.

Its one of the less common skin cancers, but melanoma is the most dangerous because it can easily spread to other parts of your body.

Melanoma tumors tend to be black or brown, but can sometimes be pink, tan or white. Anyone can get melanoma, but people with light skin are at greater risk.

UV light exposure from ultraviolet rays from the sun or indoor tanning causes most melanomas.

Treatments depend on how advanced the melanoma is and where the tumor is located. It may include surgery, radiation, chemotherapy or other therapies.

Read more about melanoma and how to treat it.

Psoriasis affects more than 8 million people in the U.S. It typically starts in the teen years or early 20s, though it can occur at any age.

When you have psoriasis, your body makes new skin cells quickly, and the cells typically build up in thick, scaly patches on the skin called plaques.

There are a number of factors that may contribute to causing psoriasis. The immune system and genetics may play a role. Certain triggers can also cause the onset of psoriasis and psoriasis flare-ups.

Psoriasis doesnt have a cure, there are medications and treatments that can help manage the condition.

Read more about psoriasis and how to treat it.

This common inflammatory skin condition causes redness of the face.

In addition to causing facial redness, if rosacea is not treated, it can cause visible blood vessels, breakouts like acne and other symptoms.

There are a number of factors that may play a role in whether you develop rosacea, but experts dont know for certain what causes the skin condition.

There is no cure for rosacea, but the condition can be managed to help keep symptoms from worsening.

Read more about rosacea and how to treat it.

Also known as cutaneous squamous cell carcinoma, this cancer develops when the squamous cells in the top layer of your skin grow out of control.

Though its linked with exposure to ultraviolet rays, squamous cell carcinoma can crop up in areas that dont get much sun. Watch out for rough, scaly patches, sores that dont heal or anything else that looks suspicious.

Squamous cell carcinoma is mainly caused by UV rays from the sun or indoor tanning.

Treatments for squamous cell carcinoma may include surgery, radiation or other therapies. Catching it early is key.

Read more about squamous cell carcinoma and how to treat it.

Read the original:
Skin Disorders: Pictures, symptoms, causes and help - TODAY - TODAY

Skin Stem Cells Comments Off on Skin Disorders: Pictures, symptoms, causes and help – TODAY – TODAY | August 13th, 2020

KUANTAN, Malaysia Some skin, eggs and tissue samples are all that remain of Malaysia's last rhino, Iman, who died last November after years of failed breeding attempts.

Now scientists are pinning their hopes on experimental stem cell technology to bring back the Malaysian variant of the Sumatran rhinoceros, making use of cells from Iman and two other dead rhinos.

"I'm very confident," molecular biologist Muhammad Lokman Md Isa told Reuters in his laboratory at the International Islamic University of Malaysia.

"If everything is functioning, works well and everybody supports us, it's not impossible."

The smallest among the world's rhinos, the Sumatran species was declared extinct in the wild in Malaysia in 2015. Once it had roamed across Asia, but hunting and forest clearance reduced its numbers to just 80 in neighbouring Indonesia.

Iman, 25, died in a nature reserve on Borneo island, following massive blood loss caused by uterine tumours, within six months of the death of Malaysia's last male rhino, Tam.

Efforts to get the two to breed had not worked.

"He was the equivalent of a 70-year-old man, so of course you don't expect the sperm to be all that good," said John Payne of the Borneo Rhino Alliance (BORA), who has campaigned for about four decades to save Malaysia's rhinos.

"It was obvious that, to increase the chances of success, one should get sperm and eggs from the rhinos in Indonesia. But right till today, Indonesia is still not keen on this."

ACROSS THE BORDER

Indonesia's environment ministry disputed accusations of cross-border rivalry as a reason why Malaysia's rhinos died out, saying talks continue on ways to work with conservationists in the neighbouring southeast Asian nation.

"Because this is part of diplomatic relations, the implementation must be in accordance with the regulation of each country," said Indra Exploitasia, the ministry's director for biodiversity conservation.

The Malaysian scientists plan to use cells from the dead rhinos to produce sperm and eggs that will yield test-tube babies to be implanted into a living animal or a closely related species, such as the horse.

The plan is similar to one for the African northern white rhinoceros, which number just two. Researchers in that effort reported some success in 2018 in producing embyronic stem cells for the southern white rhino.

But the process is still far from producing a whole new animal, say Thomas Hildebrandt and Cesare Galli, the scientists leading the research.

And even if it worked, the animals' lack of genetic diversity could pose a threat to long-term survival, Galli told Reuters.

Indonesian scientist Arief Boediono is among those helping in Malaysia, hoping success will provide lessons to help his country's rhinos.

"It may take five, 10, 20 years, I don't know," Arief added. "But there has already been some success involving lab rats in Japan, so that means there is a chance."

Japanese researchers have grown teeth and organs such as pancreas and kidneys using embryonic stem cells from rats and mice in efforts to grow replacement human organs.

For now, however, Iman's hide will be stuffed and put on display alongside Tam in a Borneo museum.

(Editing by Matthew Tostevin and Clarence Fernandez)

Originally posted here:
Back From the Dead? Stem Cells Give Hope for Revival of Malaysia's Extinct Rhinos - The New York Times

Skin Stem Cells Comments Off on Back From the Dead? Stem Cells Give Hope for Revival of Malaysia’s Extinct Rhinos – The New York Times | August 12th, 2020

After months of reviewing close to 300 beauty products and wellness facilities, and tallying, here are the best skincare products of this year, and lest we forget, your top pick! And so without further ado, here are the Beauty & Wellness Awards winners.

As technology continues to advance and discoveries are made each day,we do our part in dipping our toe in the proverbial pool of beauty toexplore the latest and greatest. Embracing the new is part of our job asinvestigative beauty aficionados, and as we dig through the recentdebuts, weve found some newbies that have found a permanent spot onour top shelf that we highly recommend checking out.

1

Best Face Cream: First Aid Beauty Ultra Repair Cream

For even the most sensitive skin, FAB delivers animpressive amount of hydration without anyirritation. The luscious whipped-cream texturespreads easily over the face, yet still holds wellenough for make-up to sit over nicely.

Ultra Repair Cream

HK$249/170g; HK$109/56.7G

2

Best Hydrating Serum: Skin Need 100% Hyaluronic Acid B5

The ultimate water magnet, thisserum locks in all the hydration youneed. Its easily absorbed, so yourskin feels fresh and clean without atrace of stickiness. The heavy doseof hyaluronic acid binds and trapsmoisture to the skin.

100% Hyaluronic Acid B5

HK$598

3

Best Reparative Formula: Wildsmith Skin Active Repair Radiance Polisher

Exfoliate to your hearts content and skinsneed the gentle grains of walnut shell androsehip-seed powder sloughs away deadskin cells and polishes the skins surface. Mixthe desired amount with any facial cleanserto create your very own scrub.

Skin Active Repair Radiance Polisher

HK$254

4

Best Body Cream: Augustinus Bader The Body Cream

A fresh launch from world-leadingstem cell and biomedical pioneerand scientist, Professor AugustinusBader, The Body Cream is officiallythe newest must-have item in bodyand skin care. Powered by thebrands patented Trigger FactorComplex (TFC8), this cellularrenewal cream reawakens dormantstem cells and results in firmer,toned skin with a reduction incellulite and stretch marks.

5

Readers Choice: Drunk Elephant F-balm

Electrolytes pump us full of hydration. And if its good to ingest. Why wouldnt it be topically? This waterfacial masque hydratant nourishes and repairs parched skin while you sleep. Its cooling effects are especially appreciated this season.

All of the Drunk Elephant products are naturally formulated and cater directly to your skins health. Oi Tak Kan, Prestige Reader

Read more:
Beauty & Wellness Awards 2020: New Kids on the Block - Prestige Online

Skin Stem Cells Comments Off on Beauty & Wellness Awards 2020: New Kids on the Block – Prestige Online | August 12th, 2020

No roars at Augusta as Masters to be played without fansNews / 12 mins ago

1 dead, 1 injured in deputy-involved shooting in Anderson Co., K-9 shot and killedNews / 20 mins ago

Going On At The Greenville LibraryEntertainment / 1 hour ago

Work It Wednesday - Skin UndertonesEntertainment / 2 hours ago

It's back to the future or forward to the past on National Vinyl Record DayEntertainment / 2 hours ago

Wellness By Design - Help With Joint Pain Using Stem CellsEntertainment / 2 hours ago

Jamarcus Tells Us What He Has Been Up To In York County SCEntertainment / 2 hours ago

Race is on to make COVID-19 changes for November electionNews / 4 hours ago

Carolina Morning Weather Aug. 12Weather / 6 hours ago

'Put forth a little bit of effort': Greenville County Schools Superintendent talks virtual learning dress codeNews / 12 hours ago

Bentley tries taking PAC-12 shutdown in strideSports / 14 hours ago

HSRZ Team Preview: Wade Hampton GeneralsSports / 14 hours ago

See the original post:
Going On At The Greenville Library - WSPA 7News

Skin Stem Cells Comments Off on Going On At The Greenville Library – WSPA 7News | August 12th, 2020

A team of researchers from several U.S. institutions has created an organoid culture system that generates complex skin from human pluripotent stem cells.

A hair-bearing skin organoid. Image credit: Indiana University School of Medicine.

This is the first study to show that human hair can be grown completely from stem cells in a dish, which has been a goal of the skin biology community for decades, said lead author Dr. Karl Koehler, from Harvard Medical School and Boston Childrens Hospital.

Through the 3D culture technique developed in past studies, Dr. Koehler and colleagues incubated human stem cells for about 150 days in a skin organoid.

Weve developed a new cooking recipe for generating human skin that produces hair follicles after about 70 days in culture, Dr. Koehler explained.

When the hair follicles grow, the roots extend outward radially. Its a bizarre-looking structure, appearing almost like a deep-sea creature with tentacles coming out from it.

After the incubation period, researchers tested whether skin organoids could integrate on the skin of nude mice. More than half of the organoids they grafted on the mice grew human hair follicles.

The skin organoid developed from culture is akin to fetal facial skin and hair, he said.

The teams experiments show that organoid generated hairy skin can integrate into mouse skin, which suggests potential applications in skin and facial reconstruction.

This could be a huge innovation, providing a potentially unlimited source of soft tissue and hair follicles for reconstructive surgeries, said first author Dr. Jiyoon Lee, also from Harvard Medical School and Boston Childrens Hospital.

Skin regeneration is of great interest for treating patients, added co-author Dr. Taha Shipchandler, from the Indiana University School of Medicine.

If we can harness this growth into a medium, and easily apply it to patients, it would change the way we treat many injuries or reconstructions. This would have a profound effect on the medical field.

The results were published in the journal Nature.

_____

J. Lee et al. Hair-bearing human skin generated entirely from pluripotent stem cells. Nature, published online June 3, 2020; doi: 10.1038/s41586-020-2352-3

Originally posted here:
Scientists Create Hair-Bearing Human Skin from Pluripotent ...

Skin Stem Cells Comments Off on Scientists Create Hair-Bearing Human Skin from Pluripotent … | August 10th, 2020

In 2007, a group of researchers reported a startling discovery: They had created sperm-like cells out of stem cells taken from the bone marrow of human men. Two years later, however, the study was retracted due to charges of plagiarism. Thirteen years later, the ability to create functional human sperm out of stem cells remains elusive.

Scientists have been trying to figure out how to create functioning human gametes eggs and sperm from stem cells for 20 or 30 years, says Vittorio Sebastiano, a stem cell biologist at Stanford University whose research focuses on reproductive biology. Doing so would help people struggling with infertility have children and help scientists unlock the secrets of human development. Since 2007, scientists have made considerable progress on this front, creating healthy mouse pups from stem cell-generated gametes and even immature human egg cells. But there is still a long road ahead before scientists will be able to convert skin or bone marrow into babies.

We are trying to really find ways to efficiently, robustly generate germ cells that can be, in the short term, used to understand the biology of these concepts, but in the long term [used to be] able to restore fertility, says Sebastiano.

When the first baby conceived via in vitro fertilization (IVF) was born in 1978, it was a major step forward for reproductive science and a precursor to the stem cell research conducted by Sebastiano and others today, he says. But IVF is not an option for every individual or couple trying to have a biological child, including those who are born without gametes or who receive aggressive cancer treatments at a young age. This scientific technique would offer these individuals a new shot at reproduction.

The next major step came in the 2000s, with the creation of induced pluripotent stem cells (iPSCs). These cells are taken from blood or skin cells and reprogrammed to behave like embryonic cells, which have the ability to develop into any type of cell in the body. Since then, researchers have been trying to figure out how to turn these embryonic-like cells into functional sperm and eggs.

A colony of induced pluripotent stem cells used to treat the rare genetic disorder Fanconi anemia. (Credit: Juan Carlos Izpisua Belmonte, Salk Institute for Biological Studies)

Part of what has made this work so challenging is that scientists havent been able to fully grasp what happens in a human embryo during normal development, says Sebastiano. Scientists understand this process in mice because the rodents are easy to study in the lab. But ethical restrictions and technical factors (like having access to the embryos at just the right point in time) make this phenomenon hard to study in people, he says.

Despite the roadblocks, scientists have made significant progress in the last 10 years. In 2012, a group of researchers in Japan created fertile mouse eggs from iPSCs and used those eggs to breed healthy mouse pups. In [the] mouse, the whole circle has already been completed, says Sebastiano. Now it has been shown by a couple of groups in the UK and in Japan that you can generate embryonic-like cells from mice and then you can actually push these cells to become eggs or sperm, fully functional.

In 2018, the same group of Japanese scientists made another major breakthrough. Using human blood cells and the pluripotent stem cell technique, they managed to produce immature human eggs.

Similar efforts to create sperm are not as far along, says Sebastiano. Several efforts over the years have purported to create sperm-like cells, including the 2007 blood marrow study. A much-heralded study published in 2014 also made major news, but Sebastiano says the development of the cells in that study didnt go far beyond the earliest stages of differentiation.

But, we are actively working on it, says Sebastiano. Probably in the next few years we will be able to generate fully functional sperm and fully functional oocytes. Then, the question will be how do scientists test the quality of these gametes, he says.

The only way to fully assess the quality and functionality of a sperm or egg is to use it to, well, try to fertilize another gamete and produce a baby. Thats why this work has to be approached with the utmost care, says Sebastiano. He hypothesizes that once scientists have developed techniques that they think produce mature human oocytes and sperm, the next step will be testing these techniques in primates. That way, researchers can follow the entire life of individual animals produced from this technique to see if any unexpected problems develop, he says.

Sebastiano has no doubt that one day, these stem cells could help individuals struggling with infertility to produce healthy children. This, along with a fascination with biological development, is what drives Sebastianos work. There are also, of course, significant ethical considerations that have to be carefully considered. This technique has the potential to affect human life on a generational level, he notes. And many people also raise concerns about other future consequences, like the ability to create designer babies or produce offspring from hairs stolen from unsuspecting celebrities. Bioethics experts have written about the need to start working through the medical and legal issues around this technique now, before it is viable.

There is a need actually to develop this, but since we are really dealing with a very unique cell type we need to be cautious, says Sebastiano.

Here is the original post:
How Close Are We To Making Babies from Bone Marrow? - Discover Magazine

Skin Stem Cells Comments Off on How Close Are We To Making Babies from Bone Marrow? – Discover Magazine | August 10th, 2020

This rebrand symbolizes our growth as a company and an opportunity to show our customers that we understand and are responding to their evolving skincare needs, Connie Lo, Three Ships Co-Founder, tells the press.

We invite anyone, adds Lo,interested in a more revitalized complexion to try our products and embark on their journey to better skin.

Connie Lo and Laura Burget founded NIU Body in early 2017 as an unpretentious, clean, and affordable skin care brand for their fellow millennials. We aspire to be an approachable option without the fancy fluff, at affordable prices so everyone can enjoy everything green beauty has to offer. Our products are simple in both design and formulation, explained Burget in her 2018 Indie Beauty Profile.

And those core brand qualities havent changed now that NIU Body is Three Ships: While our look has changed, says Burget in a press release shared with Cosmetics Design, we remain meticulous in our approach to sourcing sustainable ingredients and creating formulations that provide tangible benefits.

Our philosophy, she says,has and always will be to be the change we want to see in the beauty industry: natural, effective and affordable skincare with a conscience.

As with any thorough rebrand, the change from NIU Body to Three Ships is about more than just a new name. As the brand explains in a recent LinkedIn update, It really was a culmination of how we felt about our years-long journey discovering affordable skincare ingredients that actually worked for us. The destination always seems further than it appears, but as we journey towards it, we start to see the full picture. Three Ships is about the journey to better skin.

The brand has new packaging and labeling, based primarily on consumer feedback. And now the brands portfolio is full of skin care product names that highlight key ingredients and benefits, such as Clarify Tea Tree + MCT Cleansing Oil, Hydrate 49% Almond Oil Serum, and Awake Rose Hydrosol Toner.

In conjunction with the rebranding, Three Ships also launched a new day cream. The Radiance Grape Stem Cell + Squalene Day Cream is, according to the brands press release, a highly-requested product formulated with revolutionary grape stem cells to protect from UV damage throughout the day and fight photo-aging. Hydrating prickly pear and argan oils along with natural squalene lock in moisture leaving skin soft and radiant.

Radiance is made for all skin types to help even and balance skin tone. It's also packaged in an airless pump top jar, which prevents air exposure and helps protect the cream, increasing the shelf life naturally, notes the release.

More:
The NIU BODY Rebrand: millennials have grown up and so has their skin care - CosmeticsDesign.com USA

Skin Stem Cells Comments Off on The NIU BODY Rebrand: millennials have grown up and so has their skin care – CosmeticsDesign.com USA | August 10th, 2020